Opportunity to Partner; Testing of Patient Litters and Patient Restraints to Proposed Test Standard, 13621-13623 [2011-5733]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 49 / Monday, March 14, 2011 / Notices
unit cost of materials, per unit cost of
labor, per unit cost of design, test and
certification, etc. Data from each
manufacturer will be held confidential
by the CPA and coded to remove
corporate identifiers. The goal is to
assess the cost of change to the industry
rather than to an individual product
within a given manufacturers’ broad
product line.
Candidate companies will be
evaluated based on their capability and
willingness to work cooperatively to
achieve the stated goals. Candidates
selected will be required to enter into a
Letter of Agreement spelling out the
level of participation expected of each
partner and the handling of data
generated from the partnership. This
announcement does not obligate NIOSH
to enter into an agreement with any
respondents. NIOSH reserves the right
to establish a partnership based on the
engineering analysis and capabilities
found by way of this announcement or
other searches, if determined to be in
the best interest of the government.
NIOSH recognizes this opportunity
will raise many questions for
prospective partners. In order to give all
involved the greatest opportunity to
understand the process and project
expectations, the NTEA–AMD, our
collaborative partner and host standards
setting body, has agreed to provide a
meeting room for us to hold an
informational meeting to present a
broad overview of the effort and answer
any resulting questions.
In order to provide us with the best
opportunity to meet the needs of all
prospective partners at each of these
meetings; we request that all interested
parties contact Jim Green, NIOSH
Project Officer, by e-mail at
JGreen@cdc.gov; or telephone (304)
285–5857, by Thursday, March 17,
2011.
mstockstill on DSKH9S0YB1PROD with NOTICES
CONTACT PERSON FOR MORE INFORMATION:
Jim Green, NIOSH Project Officer, email: JGreen@cdc.gov; telephone (304)
285–5857.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: March 7, 2011.
Tanja Popovic,
Deputy Associate Director for Science,
Centers for Disease Control and Prevention.
[FR Doc. 2011–5732 Filed 3–11–11; 8:45 am]
BILLING CODE 4163–19–P
VerDate Mar<15>2010
16:20 Mar 11, 2011
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
13621
Dated: March 7, 2011.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2011–5755 Filed 3–11–11; 8:45 am]
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel; Teleconference
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Pilot for Statespecific Cross-Sectional Surveillance of
Persons with Rare Disorders and
Longitudinal Assessment of Outcomes,
Funding Opportunity Announcement
(FOA) DD11–004, and Pilot
Longitudinal Data Collection to Inform
Public Health—Fragile X Syndrome,
FOA DD11–007, initial review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Time and Date: 11 a.m.–5 p.m., April
21, 2011 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters to Be Discussed: The meeting
will include the initial review,
discussion, and evaluation of ‘‘Pilot for
State-specific Cross-Sectional
Surveillance of Persons with Rare
Disorders and Longitudinal Assessment
of Outcomes, FOA DD11–004, and Pilot
Longitudinal Data Collection to Inform
Public Health—Fragile X Syndrome,
FOA DD11–007.’’
Contact Person for More Information:
Donald Blackman, PhD, Scientific
Review Officer, Extramural Research
Program Office, National Center for
Chronic Disease Prevention and Health
Promotion, CDC, 4770 Buford Highway,
NE., Mailstop K–92, Atlanta, Georgia
30341, Telephone: (770) 488–3023, Email: DBY7@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Family History
and Diamond Blackfan Anemia, DD11–
010, Initial Review
Correction: This notice was published
in the Federal Register on January 21,
2011, Volume 76, Number 14, Page
3909. The date for the aforementioned
meeting has been changed to the
following:
DATES: April 27, 2011 (Closed).
Contact Person for More Information:
Michael Dalmat, Dr.P.H., Scientific
Review Officer, CDC, National Center
for Chronic Disease Prevention and
Health Promotion, Office of the Director,
Extramural Research Program Office,
4770 Buford Highway, NE., Mailstop K–
92, Atlanta, Georgia 30341, Telephone:
(770) 488–6423, E-mail:
MED1@CDC.GOV.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: March 7, 2011.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2011–5759 Filed 3–11–11; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Opportunity to Partner; Testing of
Patient Litters and Patient Restraints
to Proposed Test Standard
Authority: 29 U.S.C. 669.
NIOSH, Centers for Disease
Control and Prevention (CDC),
AGENCY:
E:\FR\FM\14MRN1.SGM
14MRN1
13622
Federal Register / Vol. 76, No. 49 / Monday, March 14, 2011 / Notices
Department of Health and Human
Services (HHS).
ACTION: Notice of informational meeting
and opportunity to partner.
The National Institute for
Occupational Safety and Health
(NIOSH), CDC, HHS, in collaboration
with the National Truck Equipment
Association, Ambulance Manufacturers
Division (NTEA–AMD) has developed a
series of proposed ambulance
component test standards. One such
standard, AMD STANDARD 004—
Method for Conducting Litter and Litter
Retention System Dynamic Test—
Proposed (draft), seeks to improve
patient and litter retention during crash
conditions. As a part of the standard
development process, NIOSH will be
conducting a series of tests to evaluate
existing, redesigned, and/or new litters
to validate the test methods proposed. It
is anticipated testing will be conducted
in up to three phases over
approximately 15 months. NIOSH will
contract with an independent test
facility and provide funding for all
testing, instrumentation, data collection,
and data analysis. Prospective industry
partners will provide the test assets:
Litters and litter retention devices. This
project has three key goals: (1) To
validate test and data collection
methodologies proposed in AMD 004
(draft) to support standard development;
(2) to support and facilitate the
transition of the industry from the
current litter design parameters to those
proposed in SAE J2917 Surface Vehicle
Recommended Practice, Occupant
Restraint and Equipment Mounting
Integrity—Frontal Impact System-Level
Ambulance Patient Compartment,
published May 2010, and SAE J2956
Surface Vehicle Recommended Practice,
Occupant Restraint and Equipment
Mounting Integrity—Side Impact
System-Level Ambulance Patient
Compartment (draft); and, (3) to develop
the design and production ‘‘cost-ofchange’’ to meet the proposed design
parameters.
DATES AND TIMES: March 23, 2011, 1
p.m.–5 p.m., Eastern Standard Time
(EST). March 24, 2011, 8 a.m.–12 noon,
EST, by appointment. NIOSH is
available to meet with individual
companies for those interested in
further discussion. We anticipate
offering the prospective partners the
opportunity to meet for 30 minutes, to
ask specific questions pertinent to their
situation.
ADDRESSES: Homewood Suites
Indianapolis-Downtown, 211 South
Meridian Street, Indianapolis, Indiana
46225, Telephone (317) 636–7992.
mstockstill on DSKH9S0YB1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:20 Mar 11, 2011
Jkt 223001
(Coincident with the 2011 Fire
Department Instructors Conference
(FDIC)).
Letters of Interest: Interested
manufacturers should submit a letter of
interest with information about their
capabilities and level of proposed
participation to Jim Green at
JGreen@cdc.gov. Letters of interest must
be received by April 25, 2011.
SUPPLEMENTARY INFORMATION: NIOSH
proposes a series of up to 48 tests to
better understand the capabilities and
limitations of currently available litters,
investigate redesign or new design
options, and validate the proposed test
standard. As a byproduct of this effort,
it is expected that NIOSH and its
partners will be able to demonstrate that
litters provided by partners meet the
design parameters specified in AMD 004
(draft) and test requirements outlined in
SAE J2917 and SAE 2956 (draft),
respectively.
Prospective partners will be existing
litter manufacturers nationally or
internationally. A prospective partner
need not be selling to the United States
market at the time of this
announcement.
Prospective partners will be required
to provide test assets (litters and
mounting systems) free of charge in
exchange for their participation in this
collaborative standards development
and validation effort. In return, NIOSH
will cover all costs associated with
testing. This includes the cost of the
sled buck design and manufacture,
rental of appropriate test manikins,
instrumentation related to the litter,
manikin, and sled buck, test execution,
test data analysis, and cost data
analysis.
Given the nature of the proposed
change, coupled with the cost for each
unit, NIOSH anticipates the need to
partner with more than one
manufacturer. Therefore no one
manufacturer should expect to be asked
to contribute all needed test assets.
In phase 1, test assets are expected to
come from those in the existing product
line per mutual agreement with NIOSH.
In phases 2 and 3, test assets are
expected to be introduced as either
redesigns of existing products or new
products entirely based on the results of
phase 1 testing. The cost of product
redesign and manufacture for phase 2
and 3 testing would be borne by the
manufacturer partner(s).
Each partner will be invited to
participate at the site of testing (a third
party independent test facility) during
the testing of its product. However, at
no time will representatives from two
different manufacturers be present at the
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
same time or on the same date. As a
participant, each partner will be
provided with a copy of all digital video
and instrumented data for use in future
product development. NIOSH will
retain a copy of all data but will code,
to the extent possible, to prevent release
of vendor specific product data. Partners
will retain ownership of each test asset
and will be asked to retrieve test assets
once each test has been completed. All
shipping and/or disposal costs of test
assets to and from the independent test
facility will be borne by the
manufacturer partner(s).
Recognizing any change in standard
or test requirement may have a
coincident cost; NIOSH will also be
seeking to quantify the cost of change—
that is, the cost of redesigning and
manufacturing to meet the proposed
new test standards. In this instance,
NIOSH has a separate effort in place
with an independent Certified Public
Accountant (CPA). Any participant or
partner in this effort would be required
to work with the CPA in parallel with
the test program outlined above.
Specifically, the partner would be
required to provide the underlying cost
data for each product evaluated in the
test program. This would include the
costs for a current or comparable pretest or pre-standard litter and its
companion post standard or post
redesign equivalent. Prospective
partners should be aware it may be
possible to consider a few products
within their existing product line (e.g.;
entry level, mid level, and high end
products). These costs may include: Per
unit cost of materials, per unit cost of
labor, per unit cost of design, test and
certification, etc. Data from each
manufacturer will be held confidential
by the CPA and coded to remove
corporate identifiers. The goal is to
assess the cost of change to the industry
rather than to an individual product
within a given manufacturers’ broad
product line.
Candidate companies will be
evaluated based on their capability and
willingness to work cooperatively to
achieve the stated goals. Candidates
selected will be required to enter into a
Letter of Agreement spelling out the
level of participation expected of each
partner and the handling of data
generated from the partnership. This
announcement does not obligate NIOSH
to enter into an agreement with any
respondents. NIOSH reserves the right
to establish a partnership based on the
engineering analysis and capabilities
found by way of this announcement or
other searches, if determined to be in
the best interest of the government.
E:\FR\FM\14MRN1.SGM
14MRN1
Federal Register / Vol. 76, No. 49 / Monday, March 14, 2011 / Notices
NIOSH recognizes this opportunity
will raise many questions for
prospective partners. In order to give all
involved the greatest opportunity to
understand the process and project
expectations, the NTEA–AMD, our
collaborative partner and host standards
setting body, has agreed to provide a
meeting room for us to hold an
informational meeting to present a
broad overview of the effort and answer
any resulting questions.
To provide us with the best
opportunity to meet the needs of all
prospective partners at each of these
meetings, we request that all interested
parties contact Jim Green, NIOSH
Project Officer, by email at
JGreen@cdc.gov; or telephone (304)
285–5857, by Thursday, March 17,
2011.
CONTACT PERSON FOR MORE INFORMATION:
Jim Green, NIOSH Project Officer, email: JGreen@cdc.gov; telephone (304)
285–5857.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
FOR FURTHER INFORMATION CONTACT:
Dated: March 7, 2011.
Tanja Popovic,
Deputy Associate Director for Science,
Centers for Disease Control and Prevention.
Food and Drug Administration
[FR Doc. 2011–5733 Filed 3–11–11; 8:45 am]
BILLING CODE 4163–19–P
Food and Drug Administration,
HHS.
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Medical Devices; Third Party Review
Program Under the Food and Drug
Administration Modernization Act’’ has
been approved by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
mstockstill on DSKH9S0YB1PROD with NOTICES
16:20 Mar 11, 2011
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2011–N–0116]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Medical Device
Labeling Regulations
Food and Drug Administration,
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
medical device labeling regulations.
DATES: Submit either electronic or
written comments on the collection of
information by May 13, 2011.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
SUMMARY:
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Medical Devices; Third Party Review
Program Under the Food and Drug
Administration Modernization Act
VerDate Mar<15>2010
BILLING CODE 4160–01–P
ACTION:
[Docket No. FDA–2010–N–0447]
SUMMARY:
[FR Doc. 2011–5738 Filed 3–11–11; 8:45 am]
HHS.
Food and Drug Administration
ACTION:
Dated: March 8, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5156, Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In the
Federal Register of December 28, 2010
(75 FR 81616), the Agency announced
that the proposed information collection
had been submitted to OMB for review
and clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0375. The
approval expires on February 28, 2014.
A copy of the supporting statement for
this information collection is available
on the Internet at https://
www.reginfo.gov/public/do/PRAMain.
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
13623
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, PI50–400B, Food and
Drug Administration, 1350 Piccard Dr.,
Rockville, MD 20850, 301–796–5156,
Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c)
and includes Agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal Agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information before
submitting the collection to OMB for
approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Medical Device Labeling Regulations—
(OMB Control Number 0910–0485)—
(Extension)
Section 502 of the Federal Food, Drug,
and Cosmetic Act (the FD&C Act) (21
U.S.C. 352), among other things,
establishes requirements for the label or
labeling of a medical device so that it is
not misbranded and subject to a
E:\FR\FM\14MRN1.SGM
14MRN1
]]>Agencies
[Federal Register Volume 76, Number 49 (Monday, March 14, 2011)]
[Notices]
[Pages 13621-13623]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-5733]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Opportunity to Partner; Testing of Patient Litters and Patient
Restraints to Proposed Test Standard
Authority: 29 U.S.C. 669.
AGENCY: NIOSH, Centers for Disease Control and Prevention (CDC),
[[Page 13622]]
Department of Health and Human Services (HHS).
ACTION: Notice of informational meeting and opportunity to partner.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH), CDC, HHS, in collaboration with the National Truck Equipment
Association, Ambulance Manufacturers Division (NTEA-AMD) has developed
a series of proposed ambulance component test standards. One such
standard, AMD STANDARD 004--Method for Conducting Litter and Litter
Retention System Dynamic Test--Proposed (draft), seeks to improve
patient and litter retention during crash conditions. As a part of the
standard development process, NIOSH will be conducting a series of
tests to evaluate existing, redesigned, and/or new litters to validate
the test methods proposed. It is anticipated testing will be conducted
in up to three phases over approximately 15 months. NIOSH will contract
with an independent test facility and provide funding for all testing,
instrumentation, data collection, and data analysis. Prospective
industry partners will provide the test assets: Litters and litter
retention devices. This project has three key goals: (1) To validate
test and data collection methodologies proposed in AMD 004 (draft) to
support standard development; (2) to support and facilitate the
transition of the industry from the current litter design parameters to
those proposed in SAE J2917 Surface Vehicle Recommended Practice,
Occupant Restraint and Equipment Mounting Integrity--Frontal Impact
System-Level Ambulance Patient Compartment, published May 2010, and SAE
J2956 Surface Vehicle Recommended Practice, Occupant Restraint and
Equipment Mounting Integrity--Side Impact System-Level Ambulance
Patient Compartment (draft); and, (3) to develop the design and
production ``cost-of-change'' to meet the proposed design parameters.
Dates and Times: March 23, 2011, 1 p.m.-5 p.m., Eastern Standard Time
(EST). March 24, 2011, 8 a.m.-12 noon, EST, by appointment. NIOSH is
available to meet with individual companies for those interested in
further discussion. We anticipate offering the prospective partners the
opportunity to meet for 30 minutes, to ask specific questions pertinent
to their situation.
ADDRESSES: Homewood Suites Indianapolis-Downtown, 211 South Meridian
Street, Indianapolis, Indiana 46225, Telephone (317) 636-7992.
(Coincident with the 2011 Fire Department Instructors Conference
(FDIC)).
Letters of Interest: Interested manufacturers should submit a
letter of interest with information about their capabilities and level
of proposed participation to Jim Green at JGreen@cdc.gov. Letters of
interest must be received by April 25, 2011.
SUPPLEMENTARY INFORMATION: NIOSH proposes a series of up to 48 tests to
better understand the capabilities and limitations of currently
available litters, investigate redesign or new design options, and
validate the proposed test standard. As a byproduct of this effort, it
is expected that NIOSH and its partners will be able to demonstrate
that litters provided by partners meet the design parameters specified
in AMD 004 (draft) and test requirements outlined in SAE J2917 and SAE
2956 (draft), respectively.
Prospective partners will be existing litter manufacturers
nationally or internationally. A prospective partner need not be
selling to the United States market at the time of this announcement.
Prospective partners will be required to provide test assets
(litters and mounting systems) free of charge in exchange for their
participation in this collaborative standards development and
validation effort. In return, NIOSH will cover all costs associated
with testing. This includes the cost of the sled buck design and
manufacture, rental of appropriate test manikins, instrumentation
related to the litter, manikin, and sled buck, test execution, test
data analysis, and cost data analysis.
Given the nature of the proposed change, coupled with the cost for
each unit, NIOSH anticipates the need to partner with more than one
manufacturer. Therefore no one manufacturer should expect to be asked
to contribute all needed test assets.
In phase 1, test assets are expected to come from those in the
existing product line per mutual agreement with NIOSH. In phases 2 and
3, test assets are expected to be introduced as either redesigns of
existing products or new products entirely based on the results of
phase 1 testing. The cost of product redesign and manufacture for phase
2 and 3 testing would be borne by the manufacturer partner(s).
Each partner will be invited to participate at the site of testing
(a third party independent test facility) during the testing of its
product. However, at no time will representatives from two different
manufacturers be present at the same time or on the same date. As a
participant, each partner will be provided with a copy of all digital
video and instrumented data for use in future product development.
NIOSH will retain a copy of all data but will code, to the extent
possible, to prevent release of vendor specific product data. Partners
will retain ownership of each test asset and will be asked to retrieve
test assets once each test has been completed. All shipping and/or
disposal costs of test assets to and from the independent test facility
will be borne by the manufacturer partner(s).
Recognizing any change in standard or test requirement may have a
coincident cost; NIOSH will also be seeking to quantify the cost of
change--that is, the cost of redesigning and manufacturing to meet the
proposed new test standards. In this instance, NIOSH has a separate
effort in place with an independent Certified Public Accountant (CPA).
Any participant or partner in this effort would be required to work
with the CPA in parallel with the test program outlined above.
Specifically, the partner would be required to provide the underlying
cost data for each product evaluated in the test program. This would
include the costs for a current or comparable pre-test or pre-standard
litter and its companion post standard or post redesign equivalent.
Prospective partners should be aware it may be possible to consider a
few products within their existing product line (e.g.; entry level, mid
level, and high end products). These costs may include: Per unit cost
of materials, per unit cost of labor, per unit cost of design, test and
certification, etc. Data from each manufacturer will be held
confidential by the CPA and coded to remove corporate identifiers. The
goal is to assess the cost of change to the industry rather than to an
individual product within a given manufacturers' broad product line.
Candidate companies will be evaluated based on their capability and
willingness to work cooperatively to achieve the stated goals.
Candidates selected will be required to enter into a Letter of
Agreement spelling out the level of participation expected of each
partner and the handling of data generated from the partnership. This
announcement does not obligate NIOSH to enter into an agreement with
any respondents. NIOSH reserves the right to establish a partnership
based on the engineering analysis and capabilities found by way of this
announcement or other searches, if determined to be in the best
interest of the government.
[[Page 13623]]
NIOSH recognizes this opportunity will raise many questions for
prospective partners. In order to give all involved the greatest
opportunity to understand the process and project expectations, the
NTEA-AMD, our collaborative partner and host standards setting body,
has agreed to provide a meeting room for us to hold an informational
meeting to present a broad overview of the effort and answer any
resulting questions.
To provide us with the best opportunity to meet the needs of all
prospective partners at each of these meetings, we request that all
interested parties contact Jim Green, NIOSH Project Officer, by email
at JGreen@cdc.gov; or telephone (304) 285-5857, by Thursday, March 17,
2011.
CONTACT PERSON FOR MORE INFORMATION: Jim Green, NIOSH Project Officer,
e-mail: JGreen@cdc.gov; telephone (304) 285-5857.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Dated: March 7, 2011.
Tanja Popovic,
Deputy Associate Director for Science, Centers for Disease Control and
Prevention.
[FR Doc. 2011-5733 Filed 3-11-11; 8:45 am]
BILLING CODE 4163-19-P
